To answer this intriguing question, Hess takes us into the world of alternative cancer researchers. Maintaining that their work has been actively suppressed rather than simply dismissed, Hess examines their claims - that bacterial vaccines have led to some dramatic cases of long-term cancer remission - and the scientific potential of their theories. Economic interests and cultural values, he demonstrates, have influenced the rush toward radiation and chemotherapy and the current cul-de-sac of toxic treatments.
Bacterial infections cause substantial morbidity and mortality in cancer patients. These infections always remained enigmatic due to initial reluctance of cancer researchers in understanding their etiologic potential. Etiological association of bacteria with cancer gained credibility after discovery of carcinogenic potential of Helicobacter pylori. Moreover, other suspected associations including Salmonella typhi and gallbladder cancer, Streptococcus bovis and colon cancer, Chlamydia psittaci and ocular adnexal lymphoma and Chlamydia pneumoniae with lung cancer, etc. are looking for a legitimate appraisal to unravel their etiologic potential without prejudice. In contrary, bacteria also show protective role in certain types of cancer. Certain agents derived from bacteria are successfully in practice for the management of cancer. The integrate association of bacteria and cancer is evident in both positive and negative aspects. The role of bacteria in cancer etiology and treatment is vigorously studied since last few years. Present book tries to provide current status of research undergoing in above direction, with the glimpses of future possibility for using microbiological knowledge in the management of this deadly killer. This book will interest specialists dealing with cancer associated infectious complications, researchers working in the field of cancer biology, teachers and scientists in the field of microbiology, biotechnology, medicine and oncology. The unique coverage of bacteriology and cancer association in both positive and negative way can usher into development of novel thrust area for microbiology students and experts.
Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them.
Infections must be thought as one of the most important, if not the most important, risk factors for cancer development in humans. Approximately 15-20% of all cases of cancer around the world are caused by viruses. The establishment of a causal relationship between the presence of specific infective agents and certain types of human cancer represents a key step in the development of novel therapeutic and preventive strategies. In this book, Professor zur Hausen (Nobel Prize in Physiology/Medicine 2008) provides a thorough and comprehensive overview on carcinogenic infective agents -- viruses, bacteria, parasites and protozoons -- as well as their corresponding transforming capacities and mechanisms. The result is an invaluable and instructive reference for all oncologists, microbiologists and molecular biologists working in the area of infections and cancer. The author was among the first scientists to reveal the cervical cancer-inducing mechanisms of human papilloma viruses and isolated HPV16 and HPV18, and, as early as 1976, published the hypothesis that wart viruses play a role in the development of this type of cancer.
This book ventures into a new and exciting area of discovery that directly ties our current knowledge of cancer to the discovery of microorganisms associated with different types of cancers. Recent studies demonstrate that microorganisms are directly linked to the establishment of cancers and that they can also contribute to the initiation, as well as persistence of, the cancers. Microbiome and Cancer covers the current knowledge of microbiome and its association with human cancers. It provides important reading for novices, senior undergraduates in cancer and microbiology, graduate students, junior investigators, residents, fellows and established investigators in the fields of cancer and microbiology. We cover areas related to known, broad concepts in microbiology and how they can relate to the ongoing discoveries of the micro-environment and the changes in the metabolic and physiologic states in that micro-environment, which are important for the ongoing nurturing and survival of the poly-microbial content that dictates activities in that micro-environment. We cover the interactions of microorganisms associated with gastric carcinomas, which are important for driving this particular cancer. Additional areas include oral cancers, skin cancers, ovarian cancers, breast cancers, nasopharyngeal cancers, lung cancers, mesotheliomas, Hodgkin’s and non-Hodgkin’s lymphomas, glioblastoma multiforme, hepatocellular carcinomas, as well as the inflammatory response related to the infectious agents in cancers. This book covers the metabolic changes that occur because of infection and their support for development of cancers, chronic infection and development of therapeutic strategies for detection and control of the infection. The field of microbiome research has exploded over the last five years, and we are now understanding more and more about the context in which microorganisms can contribute to the onset of cancers in humans. The field of microbiome research has demonstrated that the human body has specific biomes for tissues and that changes in these biomes at the specific organ sites can result in disease. These changes can result in dramatic differences in metabolic shifts that, together with genetic mutations, will produce the perfect niche for establishment of the particular infection programmes in that organ site. We are just beginning to understand what those changes are and how they influence the disease state. Overall, we hope to bring together the varying degrees of fluctuations in the microbiome at the major organ sites and how these changes affect the normal cellular processes because of dysregulation, leading to proliferation of the associated tissues.
The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.
Bone and soft tissue sarcomas represent only about 2% of all malignancies; however, their treatment – with the goal of curing the patient while preserving the functionality of the affected body part – can, unlike other malignancies, only be successful with therapy concepts devised by interdisciplinary teams. This volume provides an extensive up-to-date overview of the specific diagnostics and current treatment standards of these rare entities, presenting the various limb-sparing modalities for patients with bone and soft tissue sarcomas with special regard to innovative reconstructive options. The evaluation of quality of life based on validated scores and the individual methods of coping with the illness through creative artistic projects are also acknowledged and integrated in the whole concept.
Examining the enormous potential of microbiome manipulation to improve health Associations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. Bugs as Drugs provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease. In Bugs as Drugs, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: How well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response. The use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage. The association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis. Fecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes. Because systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted. If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow.
Developed by the American Cancer Society this new textbook designed for a wide range of learners and practitioners is a comprehensive reference covering the diagnosis of cancer, and a range of related issues that are key to a multidisciplinary approach to cancer and critical to cancer control and may be used in conjunction with the book, The American Cancer Society's Oncology in Practice: Clinical Management. Edited by leading clinicians in the field and a stellar contributor list from the US and Europe, this book is written in an easy to understand style by multidisciplinary teams of medical oncologists, radiation oncologists and other specialists, reflecting day-to-day decision-making and clinical practice. Input from pathologists, surgeons, radiologists, and other specialists is included wherever relevant and comprehensive treatment guidelines are provided by expert contributors where there is no standard recognized treatment. This book is an ideal resource for anyone seeking a deeper understanding of cancer prevention, screening, and follow-up, which are central to the ACS's worldwide mission on cancer control.
